STATUTORY INSTRUMENTS

2019 No. 744

The Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019

Amendment of regulation 36 (requirement for authorisation to manufacture or import investigational medicinal products)

[F1 17. In regulation 36(2), after "marketing authorization" insert "or marketing authorisation issued by the competent authority of an EEA State in accordance with Directive 2001/83/EC".**]**

F1 Reg. 17 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, **Sch. 1 para. 3**

Commencement Information

I1 Reg. 17 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, **Sch. 5 para. 1(1)**), see reg. 1

Changes to legislation:
There are currently no known outstanding effects for the The Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019, Section 17.